The 2nd iPSC-Derived Cell Therapies Summit 2022

About The Industry-Defining iPSC-Derived Cell Therapies Summit

A new era of cell therapy has well and truly arrived, with the iPSC field setting a trailblazing fire with its potential to develop fully scalable, off-the-shelf cell lines reducing the cost of goods and increasing accessibility to patients.

As the iPSC field continues to grow, advance and harness excitement, the flagship iPSC-Derived Cell Therapies Summit is reuniting industry leaders for the second time to tackle the challenges impeding development. Join us in Boston this December to review the latest updates and innovations from our 30+ world-class speaker faculty. Over two days and two tracks of content, you'll hear exclusive case studies, presentations and panel discussions with industry pioneers such as Century Therapeutics, Healios K.K., Sana BiotechnologyTakeda and many more. 

Explore approaches to boost safe gene-editing, approach regulatory affairs, turbocharge scale-up, optimize analytics and more to produce best-in-class therapies for immuno-oncology and regenerative medicine. 

The industry-trusted 2nd iPSC-Derived Cell Therapies Summit provides a dedicated forum to voice challenges, collaborate and spark conversations with the community committed to advancing iPSC-derived treatments. Take home new learnings and key insights from your peers to create high-quality, scalable, and affordable therapies.  

In 2021 We Hosted:

  • 110+ Attendees
  • 69 Companies 
  • 5+ Hours of Networking 
  • 4 Expert Partners 

In 2022 We Look Forward To:

  • 150+ Attendees
  • Brand New CMC & Regulatory Track
  • 30+ Expert Speakers
  • 12 New Speaking Companies
  • 79% New Speaker Faculty
  • Face-to-Face Networking

Join Your Peers To:


Connect and collaborate with leaders in the field, including Novo Nordisk, Century Therapeutics and Harvard Medical School, to overcome developmental hurdles 


Develop efficient differentiation and cell engineering protocol to produce efficacious products without genomic instability with Vita Therapeutics, Exacis Biotherapeutics and SQZ Biotech

Business (002)

Accelerate iPSC-specific analytical development to enhance cell characterization and set robust release criteria with Aspen Neuroscience and Sana Biotechnology  


Develop scalable end-to-end manufacturing processes to successfully produce iPSC products on a clinical and commercial scale with HebeCell and University of Minnesota 


Enhance iPSC therapy potency and persistence whilst guaranteeing safety and preventing immunogenicity with Sana Biotechnology and Cytovia Therapeutics 

Who Will You Meet?

150+ industry experts dedicated to advancing all aspects of iPSC development from translation to analytics to manufacturing, as well as the pioneers working to create the next generation of iPSC-derived cell therapies

2021 Attendees Included:

2022 Company Logos - iPSC (1880 × 800 px)

"Novel therapeutics are urgently needed and iPSC sourcing provides a uniquely valuable platform on which to design and develop new cancer therapeutics. Sharing and understanding the technologic advances, challenges, and strategies will allow for improved investments and approaches"
CMO, Cytovia Therapeutics

"iPSC Manufacturing Summit 2022 was a huge success filled with scientific and technological rigor, great collaborative spirit, excellent expertise in analytical and regulatory areas and inspirational vision for iPSC-Derived cell therapy!"
Chief Scientific Officer, Aspen Neuroscience

"iPSCs are one of the most complex cell typed and accordingly there are many unique biological, clinical and regulatory challenges. Sharing experiences with peers should greatly expedite the broader clinical applications of these remarkable cells: making promise real."
Chief Scientific Officer, Cartherics